At the news
? BULLISHIMPACT 6/10 6-K filed Aug 13, 2026 at 06:06 ET
Pharming announced the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4+, following NHI drug price list inclusion. Japan is the first market where Joenja is available for children aged 4-11. This expands Pharming's global footprint into a new geography with a partner handling distribution, but no revenue or financial guidance was provided.
- Joenja (leniolisib) commercially launched in Japan for APDS patients aged 4+
- Japan is the first market where Joenja is available for children aged 4-11
- Launch follows MHLW approval in March 2026 and NHI drug price list inclusion
- OrphanPacific, Inc. is the Marketing Authorization Holder responsible for supply and distribution
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access